Synthetic Antigens Enable CAR-T Cell Targeting of Solid Tumors
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
July 2025
Developing CAR-T Therapies Against Novel Cancer Antigens
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications